Compare Pfizer Inc (PFE) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Pfizer Inc trades at $27.9 (market cap $158.56B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $214.28 (market cap $39.15B). The key difference: Pfizer Inc is far larger — about 4.1× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and Pfizer Inc pays a 6.18% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 110 Days on average.
| PFE | TTWO | |
|---|---|---|
Market Cap | $158.56B | $39.15B |
Volume | 44,138,282 | 2,708,429 |
Sector | Health | Technology |
52-Week High | $29.02 | $262.29 |
52-Week Low | $23.67 | $189.69 |
Typical Hold Time | 158 Days | 110 Days |
Enterprise Value | $210.06B | $40.27B |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Take-Two Interactive trades at $204.01, up 0.73% with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth to $5.63B but faces profitability challenges with a -79.51% net margin. Analyst consensus remains strongly bullish with a $292.30 price target, supported by GTA VI's confirmed November 2026 launch. Cash flow improved significantly to $457M in 2025, though debt-to-asset ratio rose to 39.87%.
The stock presents a high-risk, high-reward opportunity with GTA VI as the primary catalyst. While current fundamentals show losses, the 79% buy rating reflects optimism for the upcoming release. Key risks include execution on the major title launch, competitive pressure, and the company's elevated debt levels. Near-term performance will likely hinge on pre-launch momentum and Q3 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
